Dr. Glen Pyle
Heart Failure, Cardiovascular Pharmacology, Molecular Biology of Heart Disease, Translational Research, Cardiovascular Physiology, Proteomics of Heart Disease
Ph.D (physiology and biophysics) (Tennessee)
Post-doctoral Fellowship, Physiology and Biophysics (Illinois)
Heart and Stroke Foundation of Canada, New Investigator Award
Heart and Stroke Foundation of Ontario, Dr Maureen Andrews Award
Canada Institutes of Health Research, James Hogg Young Investigator Award
Premier's Research Excellence Award
Canadian Cardiovascular Society Young Investigator Award
Richard J. Bing Award (International Society for Heart Research)
Our laboratory is interested in the cellular and molecular mechanisms of heart failure, and the identification of novel treatment strategies. We are examining how the Z-disc protein CapZ is altered in failing hearts, and have begun to investigate the therapeutic potential of this protein. In a separate project we are also investigating how estrogen receptors regulate heart function. Studies underway will determine how estrogen receptor control of the heart changes in models of menopause, with the objective of undertstanding some of the conflicting results from hormonal replacement therapy (HRT) studies. Finally, in a collaborative study with Drs Lynne O'Sullivan and Michael O'Grady, we have begun an investigation to determine the molecular basis for naturally occurring dilated cardiomyopathy (DCM) in Doberman Pinschers.
Projects Recently Completed:
1. Cardiac actin capping protein reduction and protein kinase C inhibition maintain myofilament function during cardioplegic arrest. Yang FH, Pyle WG. Cell Physiol Biochem. 2011;27(3-4):263-72. This study examined the role of CapZ in hearts stored for transplantation.
2. Relaxin alters cardiac myofilament function through a PKC-dependent pathway. Shaw EE, Wood P, Kulpa J, Yang FH, Summerlee AJ, Pyle WG. Am J Physiol Heart Circ Physiol. 2009 Jul;297(1):H29-36. This study investigated the impact and molecular mechanisms of action of the pregnancy hormone relaxin on cardiac contractility.
3. Cardiac myofilament regulation by protein phosphatase type 1alpha and CapZ. Yang F, Aiello DL, Pyle WG. Biochem Cell Biol. 2008 Feb;86(1):70-8. This study is a continuation of work investigating the role of CapZ in molecular signaling to cardiac myofilaments.
4. O'Sullivan ML, Pyle WG, O'Grady MR, Dawson JF. Evaluation of ten genese encoding cardiac proteins in Doberman pinschers with dilated cardiomyopathy. Am J Vet Res 2011, in press. This study represented our initial screening of genetic material from Doberman pinschers afflicted with DCM.
Projects in Progress:
Control of cardiac contractility by the estrogen receptors alpha, beta, and GPR30/GPER.
Changes in estrogen receptor regulation of cardiac function in models of menopause.
Cardioprotective potential of the Z-disc protein CapZ.
Molecular changes in myocardium of Doberman pinschers afflicted with DCM.
Control of myocardial function and intracellular signaling by phytoestrogens.
1. Langendorff perfusion set-up
2. Isolated myocyte system
3. SI Heidelberg Muscle Research System (MKB and OPT)
4. Immunoblot analysis
5. Phosphoprotein system
Administrative and Professional Activites/Interests:
1. Editorial Board, Journal of Molecular and Cellular Cardiology
2. DVM Admissions Committee
3. Acting Chair, Department of Biomedical Sciences
4. Research Advisory Committee (OVC)
5. Graduate Programme Committee
6. Reviewer for Journal of Molecular and Cellular Cardiology, American Journal of Physiology, Journal of Pharmacy and Physiology, European Journal of Physiology, Biochemistry and Cell Biology, Journal of Cellular Biochemistry
Heart and Stroke Foundation of Canada (New Investigator), Heart and Stroke Foundation of Ontario (Operating and scholarships), Canadian Institutes of Health Research, Government of Ontario, Pet Trust
Personal Lab Page
Departmental Faculty Page
Dr. Liz Sinclair
Feng Hua Yang
1. Yang FH, Pyle WG. Cardiac actin capping protein reduction and protein kinase C inhibition maintain myofilament function during cardioplegic arrest. Cell Physiol Biochem. 2011; 27(3-4): 263-72.
2. Shaw EE, Wood P, Kulpa J, Yang FH, Summerlee AJ, Pyle WG. Relaxin alters cardiac myofilament function through a PKC-dependent pathway. Am J Physiol Heart Circ Physiol. 2009; 297(1): H29-36.
3. Yang F, Aiello DL, Pyle WG. Cardiac myofilament regulation by protein phosphatase type 1alpha and CapZ. Biochem Cell Biol. 2008; 86(1): 70-8.
4. Pyle WG, La Rotta G, de Tombe PP, Sumandea MP, Solaro RJ. Control of cardiac myofilament activation and PKC-betaII signaling through the actin capping protein, CapZ. J Mol Cell Cardiol. 2006; 41(3):537-43.